Global Iduronate 2 Sulfatase 麻豆原创 Research Report 2024

Publication ID:

PB502242126

Publication Date:

March 5, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.
The global Iduronate 2 Sulfatase market was valued at US$ 914 million in 2023 and is anticipated to reach US$ 1295.1 million by 2030, witnessing a CAGR of 4.9% during the forecast period 2024-2030.
Iduronate 2-sulfatase (IDS) is a sulfatase enzyme associated with Hunter syndrome. Iduronate 2-sulfatase is required for the lysosomal degradation of heparan sulfate and dermatan sulfate. Mutations in this X-chromosome gene that result in enzymatic deficiency lead to Hunter syndrome.
This report aims to provide a comprehensive presentation of the global market for Iduronate 2 Sulfatase, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Iduronate 2 Sulfatase.
Report Scope
The Iduronate 2 Sulfatase market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Iduronate 2 Sulfatase market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Iduronate 2 Sulfatase companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
AngioChem
ArmaGen
Bioasis Technologies
Green Cross
JCR Pharmaceuticals
Esteve
RegenxBio
Sangamo BioSciences
Takeda
Segment by Type
Alpha L Iduronate Sulfate Sulfatase
Idursulfase
IDS
EC 3.1.6.13
Segment by Application
Hospitals
Ambulatory Surgical Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Iduronate 2 Sulfatase companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Iduronate 2 Sulfatase 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Alpha L Iduronate Sulfate Sulfatase
1.2.3 Idursulfase
1.2.4 IDS
1.2.5 EC 3.1.6.13
1.3 麻豆原创 by Application
1.3.1 Global Iduronate 2 Sulfatase 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Iduronate 2 Sulfatase 麻豆原创 Perspective (2019-2030)
2.2 Iduronate 2 Sulfatase Growth Trends by Region
2.2.1 Global Iduronate 2 Sulfatase 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Iduronate 2 Sulfatase Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Iduronate 2 Sulfatase Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Iduronate 2 Sulfatase 麻豆原创 Dynamics
2.3.1 Iduronate 2 Sulfatase Industry Trends
2.3.2 Iduronate 2 Sulfatase 麻豆原创 Drivers
2.3.3 Iduronate 2 Sulfatase 麻豆原创 Challenges
2.3.4 Iduronate 2 Sulfatase 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Iduronate 2 Sulfatase Players by Revenue
3.1.1 Global Top Iduronate 2 Sulfatase Players by Revenue (2019-2024)
3.1.2 Global Iduronate 2 Sulfatase Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Iduronate 2 Sulfatase 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Iduronate 2 Sulfatase Revenue
3.4 Global Iduronate 2 Sulfatase 麻豆原创 Concentration Ratio
3.4.1 Global Iduronate 2 Sulfatase 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Iduronate 2 Sulfatase Revenue in 2023
3.5 Iduronate 2 Sulfatase Key Players Head office and Area Served
3.6 Key Players Iduronate 2 Sulfatase Product Solution and Service
3.7 Date of Enter into Iduronate 2 Sulfatase 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Iduronate 2 Sulfatase Breakdown Data by Type
4.1 Global Iduronate 2 Sulfatase Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Iduronate 2 Sulfatase Forecasted 麻豆原创 Size by Type (2025-2030)
5 Iduronate 2 Sulfatase Breakdown Data by Application
5.1 Global Iduronate 2 Sulfatase Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Iduronate 2 Sulfatase Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Iduronate 2 Sulfatase 麻豆原创 Size (2019-2030)
6.2 North America Iduronate 2 Sulfatase 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Iduronate 2 Sulfatase 麻豆原创 Size by Country (2019-2024)
6.4 North America Iduronate 2 Sulfatase 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Iduronate 2 Sulfatase 麻豆原创 Size (2019-2030)
7.2 Europe Iduronate 2 Sulfatase 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Iduronate 2 Sulfatase 麻豆原创 Size by Country (2019-2024)
7.4 Europe Iduronate 2 Sulfatase 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Iduronate 2 Sulfatase 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Iduronate 2 Sulfatase 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Iduronate 2 Sulfatase 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Iduronate 2 Sulfatase 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Iduronate 2 Sulfatase 麻豆原创 Size (2019-2030)
9.2 Latin America Iduronate 2 Sulfatase 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Iduronate 2 Sulfatase 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Iduronate 2 Sulfatase 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Iduronate 2 Sulfatase 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Iduronate 2 Sulfatase 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Iduronate 2 Sulfatase 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Iduronate 2 Sulfatase 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AngioChem
11.1.1 AngioChem Company Detail
11.1.2 AngioChem Business Overview
11.1.3 AngioChem Iduronate 2 Sulfatase Introduction
11.1.4 AngioChem Revenue in Iduronate 2 Sulfatase Business (2019-2024)
11.1.5 AngioChem Recent Development
11.2 ArmaGen
11.2.1 ArmaGen Company Detail
11.2.2 ArmaGen Business Overview
11.2.3 ArmaGen Iduronate 2 Sulfatase Introduction
11.2.4 ArmaGen Revenue in Iduronate 2 Sulfatase Business (2019-2024)
11.2.5 ArmaGen Recent Development
11.3 Bioasis Technologies
11.3.1 Bioasis Technologies Company Detail
11.3.2 Bioasis Technologies Business Overview
11.3.3 Bioasis Technologies Iduronate 2 Sulfatase Introduction
11.3.4 Bioasis Technologies Revenue in Iduronate 2 Sulfatase Business (2019-2024)
11.3.5 Bioasis Technologies Recent Development
11.4 Green Cross
11.4.1 Green Cross Company Detail
11.4.2 Green Cross Business Overview
11.4.3 Green Cross Iduronate 2 Sulfatase Introduction
11.4.4 Green Cross Revenue in Iduronate 2 Sulfatase Business (2019-2024)
11.4.5 Green Cross Recent Development
11.5 JCR Pharmaceuticals
11.5.1 JCR Pharmaceuticals Company Detail
11.5.2 JCR Pharmaceuticals Business Overview
11.5.3 JCR Pharmaceuticals Iduronate 2 Sulfatase Introduction
11.5.4 JCR Pharmaceuticals Revenue in Iduronate 2 Sulfatase Business (2019-2024)
11.5.5 JCR Pharmaceuticals Recent Development
11.6 Esteve
11.6.1 Esteve Company Detail
11.6.2 Esteve Business Overview
11.6.3 Esteve Iduronate 2 Sulfatase Introduction
11.6.4 Esteve Revenue in Iduronate 2 Sulfatase Business (2019-2024)
11.6.5 Esteve Recent Development
11.7 RegenxBio
11.7.1 RegenxBio Company Detail
11.7.2 RegenxBio Business Overview
11.7.3 RegenxBio Iduronate 2 Sulfatase Introduction
11.7.4 RegenxBio Revenue in Iduronate 2 Sulfatase Business (2019-2024)
11.7.5 RegenxBio Recent Development
11.8 Sangamo BioSciences
11.8.1 Sangamo BioSciences Company Detail
11.8.2 Sangamo BioSciences Business Overview
11.8.3 Sangamo BioSciences Iduronate 2 Sulfatase Introduction
11.8.4 Sangamo BioSciences Revenue in Iduronate 2 Sulfatase Business (2019-2024)
11.8.5 Sangamo BioSciences Recent Development
11.9 Takeda
11.9.1 Takeda Company Detail
11.9.2 Takeda Business Overview
11.9.3 Takeda Iduronate 2 Sulfatase Introduction
11.9.4 Takeda Revenue in Iduronate 2 Sulfatase Business (2019-2024)
11.9.5 Takeda Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

AngioChem
ArmaGen
Bioasis Technologies
Green Cross
JCR Pharmaceuticals
Esteve
RegenxBio
Sangamo BioSciences
Takeda

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.